Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other financing activities (2016 - 2024)

Kiora Pharmaceuticals' Other financing activities history spans 8 years, with the latest figure at -$1136.0 for Q2 2024.

  • For Q2 2024, Other financing activities fell 100.18% year-over-year to -$1136.0; the TTM value through Mar 2025 reached -$1136.0, down 100.06%, while the annual FY2024 figure was $1.2 million, 63.24% up from the prior year.
  • Other financing activities reached -$1136.0 in Q2 2024 per KPRX's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.2 million in Q1 2024 to a low of -$644753.0 in Q3 2023.
  • Average Other financing activities over 3 years is $302221.8, with a median of $291241.0 recorded in 2020.
  • Peak YoY movement for Other financing activities: surged 646909.09% in 2020, then plummeted 100.18% in 2024.
  • A 3-year view of Other financing activities shows it stood at $498197.0 in 2020, then increased by 29.42% to $644753.0 in 2023, then plummeted by 100.18% to -$1136.0 in 2024.
  • Per Business Quant, the three most recent readings for KPRX's Other financing activities are -$1136.0 (Q2 2024), $1.2 million (Q1 2024), and $644753.0 (Q4 2023).